Supernus Pharmaceuticals Inc

Healthcare · Drug Manufacturers - Specialty & Generic

42.80$ +0.9% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Income Statement

Supernus Pharmaceuticals Inc (SUPN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 219 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement SUPN
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	57	62	58	76	80	88	90	100	103	116	85	105	102	100	95	127	155	144	131	141	148	159	153	170	177	167	154	136	154	164	144	168	176	174	150	165	192	212	208	219	830
Cost of Revenue	3.4	3.8	2.9	3.9	4.3	4.2	3.3	3.7	4.2	4.2	3.7	4.0	4.8	4.1	4.2	8.4	21	19	15	25	18	17	18	20	26	23	23	21	20	20	16	18	18	26	16	17	19	23	23	34	99
Gross Profit	53	59	55	72	76	84	87	96	99	112	82	101	97	96	91	118	134	125	116	116	130	142	135	150	151	144	130	114	134	145	127	150	158	148	134	149	173	189	184	185	731
Research & Development	7.9	13	9.6	11	13	16	19	20	20	30	15	17	17	20	19	22	17	18	34	15	20	21	21	16	20	18	21	24	23	23	25	26	29	29	27	22	29	28	39	29	126
Selling, General & Administrative	26	23	22	25	31	26	29	29	29	29	10	9.6	9.8	27	13	19	16	20	23	21	21	102	30	27	27	26	28	27	26	26	27	27	15	25	27	28	103	39	125	41	308
Total Operating Expenses	34	42	38	46	54	50	56	60	61	72	56	58	58	56	62	73	78	82	103	82	98	152	133	138	153	110	125	132	126	146	130	128	117	127	144	136	233	175	193	243	844
Operating Income	20	16	17	26	22	34	31	36	37	40	25	43	40	41	29	46	56	43	13	34	33	7.2	2.0	11	-1.5	34	5.2	-18	8.1	-1.0	-3.2	23	41	21	-10	12	-60	14	-7.4	-58	-112
Interest Expense	1.2	1.0	1.0	0.2	0.2	0.2	1.4	5.5	5.6	5.6	5.9	5.4	5.7	5.9	5.8	5.8	6.1	6.1	6.1	5.5	5.9	5.9	1.9	1.8	1.7	1.6	1.5	0.9	0.0	4.8	0.0	0.0	0.0	0.0	–	0.0	–	–	–	2.3	–
Pre-Tax Income	19	16	16	26	23	35	31	34	36	39	24	43	40	41	29	47	53	40	11	31	29	2.1	15	11	-0.4	35	9.0	-17	9.9	1.0	0.2	26	45	26	-5.8	17	-58	-1.9	-6.0	-58	-123
Income Tax Expense	-43	1.2	5.9	9.1	6.9	21	4.8	3.1	8.4	13	5.9	10	11	7.8	7.5	13	13	8.9	5.2	7.5	7.4	-0.4	-11	3.5	-2.2	9.7	-7.9	-16	26	-0.2	0.1	6.4	6.4	11	6.0	-5.8	-13	2.2	-3.7	0.7	-14
Net Income	62	14	10	17	16	14	26	31	28	26	18	33	29	33	22	35	40	31	5.7	24	22	2.4	26	7.9	1.7	25	17	-0.8	-16	1.2	0.1	20	38	15	-12	22	-45	-4.1	-2.3	-58	-110
EBITDA	20	17	18	27	27	36	33	38	39	56	32	50	41	48	37	56	67	51	24	43	42	21	38	35	23	58	31	4.5	32	23	17	39	65	45	18	38	-33	27	20	-30	-16

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings